In Silico Drug Discovery Market Size, Share and Trends Analysis, By Type (Software and Services), By Workflow (Target Identification & Validation, Hit Identification, Lead Optimization, and Preclinical & Clinical Trial Simulation), By Technology, By Type of Molecule, By Therapeutic Area, and End-Use, and By Region, Forecast 2025-2032

In Silico Drug Discovery Market Overview and Key Insights:

The in silico drug discovery market size reached USD 3,254.7 million in 2024 and is expected to register a revenue CAGR of 13.2% during the forecast period. In silico drug design, also known as computer-aided drug design (CADD), use computational approaches and models to uncover drug-like compounds utilizing bioinformatics tools. In silico approaches examine and forecast possible drug candidates’ biological activity, as well as their physical qualities.

Market Drivers:

Expanding use in pharmaceuticals and healthcare is a key driver of revenue growth in the in silico drug discovery market. Drug design and development is a complex and expensive process that entails discovering and producing new chemical compounds that can be utilized to cure ailments. Traditional drug design techniques are time-consuming and labour-intensive. Modern drug discovery methodologies, such as in silico technologies, have evolved as a means of reducing the cost, time, and labour necessary in the drug discovery process, thereby overcoming the disadvantages of conventional methods.

The NIH’s Biomedical Research and Development Price Index (BRDPI) shows that each approved medicine requires an average of USD 2.83 billion in R&D expenditures, encompassing pre-clinical and post-approval studies. Accounting for capital costs, the average total lifetime R&D investment per authorized medicine was USD 3.56 billion. In-silico drug discovery has led to the identification of numerous intriguing medicinal candidates. For example, in-silico approaches were used to identify the HIV therapy drug raltegravir. Another example is the cancer medicine vemurafenib, which was discovered via virtual screening. The discipline of CADD is rapidly evolving, with approaches and methodologies being actively developed. Over the last few years, the combination of biological big data and machine learning methodologies has created new opportunities to improve the accuracy and efficiency of in silico drug development.

On October 2024, Mitsubishi Gas Chemical Company, Inc. and Veritas In Silico, Inc. announced the signing of a Memorandum of Understanding (MOU) for a joint venture focused on the research, development, and production of novel oligonucleotide therapies that target RNA. VIS’s proprietary ibVIS drug discovery platform includes in silico target identification, high-throughput screening, and optimized technologies for mRNA-targeted medicines.

Market Opportunity:

Integration with digital twins & multi-omics act as an opportunity for in silico drug discovery market. Recent developments in computational biology, artificial intelligence (AI), and regulatory science are quickly replacing the conventional emphasis on animal and early-phase human trials in drug development. On April 2025, the United States Food and Drug Administration announced a significant decision to phase out obligatory animal testing for numerous drug categories, marking a trend toward in silico methods.

In silico models that effectively predict long-term disease development and stratify patients using digital biomarkers could have steered these projects or discovered futility sooner. In research and development, digital twins can be used to generate computational models of diseases, allowing scientists to run billions of virtual tests based on human biology. These digital twins are generated by reverse-engineering both known and previously unknown genetic and molecular connections that influence clinical outcomes.

On April 2025, Unlearn, a leader in AI-powered clinical trial solutions, has announced a cooperation with Trace Neuroscience. The collaboration will help Trace Neuroscience prepare its next Phase 1/2 clinical trial in amyotrophic lateral sclerosis (ALS) with Unlearn’s Digital Twin Generator for ALS (ALS DTG) and the Unlearn Platform. Trace Neuroscience will benefit from the cooperation by utilizing Unlearn’s ALS DTG, a unique machine-learning model trained on over 13,000 longitudinal clinical records from sources such as APST, PRO-ACT, and NEALS.

Recent Trends:

Emerging trends include Machine learning and Artificial Intelligence (AI), High-Performance Computing (HPC), advancement in structural biology, and hotspot grafting.

AI’s primary application in drug development is the design of new compounds with precise features and activities. Traditional approaches frequently rely on identifying and modifying existing molecules, which can be a time-consuming and laborious procedure. AI-based techniques, on the other hand, allow for the rapid and efficient design of new compounds with desirable properties and activities. For example, a deep learning (DL) algorithm was recently trained on a dataset of known drug compounds and their corresponding properties to propose new therapeutic molecules with desirable properties such as solubility and activity, demonstrating the potential of these methods for rapid and efficient drug candidate development.

On June 2025, researchers at the Massachusetts Institute of Technology (MIT) Jameel Clinic for Machine Learning in Health have announced the open-source release of Boltz-2, which predicts molecular binding affinity with unprecedented speed and accuracy, democratizing commercial drug discovery. The model is provided under the very permissive MIT license, which allows commercial drug developers to use it internally while including their own proprietary data.

Restraints & Challenges:

Despite the enormous potential and significant influence of in silico drug development, some problems persist. Many prediction models produce amazing results, but they are limited by the flaws inherent in the approximations used. While docking algorithms can anticipate binding modes, scoring methods do not always precisely estimate binding free energies, resulting in false positives or negatives.

The efficiency of computational models is strongly reliant on the quality and completeness of input data. Discrepancies in experimental data, a lack of standardized datasets, and heterogeneous data sources can all reduce the robustness of in silico predictions. High-quality simulations, especially those requiring long-timescale MD simulations at atomistic resolution or quantum chemical techniques, necessitate significant processing resources. Although developments in technology and cloud computing have alleviated this issue, the computational cost remains high for some applications.

Type Segment Insights and Analysis:

Based on the type, the in silico drug discovery market is segmented into software and services.

Software segment contributed the highest market share in 2024. Software is further sub-segmented into molecular modeling & simulation software, docking software, virtual screening tools, bioinformatics platforms, and others. Drug research and development is a complex, time-consuming, and multidisciplinary endeavor. The primary advantage of in-silico drug design is that it is less expensive to conduct drug research and development. In-silico drug design uses a variety of technologies, including Grid computing, window-based general PBPK/PD modeling software, PKUDDS for structure-based drug design, APIS, JAVA, Perl, and Python, as well as software libraries.

Protein structures are more conserved than DNA sequences, therefore measurable levels of sequence similarity usually imply significant structural similarity. Bioinformatics software applications are used to construct the target’s 3D structure using known 3D templates. The Modeller is a common tool for homology modelling, and the SWISS-model repository is a collection of protein structures generated using homology modelling.

On July 2025, BioDuro, a globally trusted Contract Research, Development, and Manufacturing Organization (CRDMO), and Atombeat Inc., a leader in AI for drug discovery, have announced a strategic partnership to develop an AI-powered platform for rapid peptide drug development. Atombeat’s unique Hermite software and RiDYMO platform, together with innovations like Reinforced Dynamics, Uni-Dock, Uni-FEP, and Uni-QSAR, accelerate AI-driven drug discovery. These technologies use advanced computer modeling, artificial intelligence, and specialized data to investigate a vast digital library of over one trillion possible peptide compounds derived from more than 1000 natural and synthetic amino acids.

Technology Segment Insights and Analysis:

Based on the technology, the in silico drug discovery market is segmented into de novo drug design, flexible ligand and flexible receptor docking, molecular dynamics simulations, scaffold hopping, and molecular docking.

De novo drug design segment contributed the largest market share in 2024. De novo drug design is a computer method for creating unique chemical structures from atomic building pieces with no predetermined associations. It is predicted that just 5 out of every 5000 drug candidates progress from preclinical to human testing, and only one of those studied in humans makes it to market. De novo drug design has several advantages, including the ability to explore a larger chemical space, design compounds that constitute original intellectual property, the potential for novel and improved therapies, and the development of therapeutic candidates in a cost- and time-efficient manner.

Newer programs take a fragment-based approach, which is generally more synthetically possible, but the final molecules are less varied. Furthermore, fragments produced by cleaving drug molecules have been found to produce ligands with greater drug-like characteristics. De novo/fragment-based drug design programs include LUDI, LigBuilder, ACFIS, and SEED.

On January 2023, Absci Corporation, a generative AI drug creation business, has announced the capacity to create and validate de novo antibodies in silico using zero-shot generative AI. This new technology represents a significant industry shift, enabling the delivery of breakthrough treatments to every patient with the touch of a button.

Therapeutic Area Segment Insights and Analysis:

Based on the therapeutic area, the in silico drug discovery market is segmented into oncology, neurology, infectious diseases, cardiovascular disorders, metabolic disorders, immunology & inflammatory diseases, and rare & orphan diseases.

Metabolic disorders segment contributed the largest market share in 2024. According to the International Diabetes Federation (IDF), in 2024, an estimated 589 million persons aged 20 to 79 would have diabetes. The total number of individuals living with diabetes expected to reach 853 million by 2050. More than 90% of diabetics suffer from type 2 diabetes, which socioeconomic, demographic, environmental, and genetic factors cause.

In silico methods, which simulate metabolic pathways and predict undesirable effects, serve an important role in directing early-stage drug selection, optimizing lead structures, and minimizing reliance on costly and time-consuming in vitro and in vivo research. These predictions assist researchers in anticipating metabolic liabilities, developing drugs with higher metabolic stability, and prioritizing experimental validation for the most promising candidates. For example, pharmaceutical researchers frequently use Lhasa’s Meteor software module to forecast possible metabolites and detect metabolic “soft spots” early in drug development, enabling them to design molecules with greater metabolic stability.

On May 2022, Oxford Drug Design Limited (ODD), a biotechnology startup, has raised GBP 2.2 million in finance from current investors ACF Investors, o2h Ventures, Meltwind Advisory, many returning angels and new investors, as well as the US-based R42 Group. The Oxford University spinoff has developed a proprietary artificial intelligence (AI) platform for drug discovery that focuses on unmet therapeutic needs in oncology.

Geographical Outlook:

In silico drug discovery market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America In Silico Drug Discovery Market:

North America is registered to have highest market share in in silico drug discovery market in 2024. This is mainly driven by rising chronic disorders, advancements in AI, machine learning, and big data analytics, and high demand for targeted & personalized medicines. According to the American Cancer Society, in 2025, 2,041,910 new cancer cases and 618,120 cancer deaths are expected in the United States. Every day, around 340 individuals die from lung cancer, which is nearly 2.5 times the number of people who die from CRC, the second leading cause of cancer death. In 2024, cigarette smoking will be directly responsible for around 101,300 of the 125,070 lung cancer deaths (81%), with an additional 3500 induced by second-hand smoke.

On April 2024, POLARISqb, the industry leader in harnessing quantum computing to accelerate drug development, has announced the release of Quantum-Aided Drug Design (QuADD). QuADD is a subscription-based SaaS tool that quickly generates a library of top candidate compounds for therapeutic targets. To locate a novel preclinical lead, start by creating a library of small compounds that could interact with the target protein binding pocket. QuADD’s novel approach converts the library construction problem into an optimization problem that can be solved using a quantum annealing computer.

Asia Pacific In Silico Drug Discovery Market:

Asia Pacific is expected to register the fastest growth rate during the forecasted period, driven by advancements in AI, machine learning, and big data analytics, high demand for targeted & personalized medicines, and growing adoption of cloud-based platforms. The Asia-Pacific (APAC) region is rapidly emerging as a leader in AI-powered drug development, thanks to solid research ecosystems and strong industry engagement. Substantial investments, cutting-edge technologies, and smart collaborations are improving drug development efficiency. Furthermore, several governments in the region are providing significant funding and policy support to encourage the expansion of AI in healthcare, further fueling innovation and success in the drug discovery space.

On October 2024, D-Wave Quantum Inc., a leader in quantum computing systems, software, and services and the world’s first commercial supplier of quantum computers, and Japan Tobacco Inc.’s pharmaceutical division announced plans to collaborate on a joint proof-of-concept project that will use quantum computing technology and artificial intelligence in the drug discovery process, dubbed “Quantum AI-driven Drug Discovery.” The project’s purpose is to develop a novel method for discovering ‘first-in-class’ medicinal small molecules.

Europe In Silico Drug Discovery Market:

Europe is expected to have considerable market share in 2024. Collaborations between international firms and European startups are especially prevalent, as they promote knowledge transfer and the co-development of cutting-edge Computer Aided Drug Discovery Cadd Services products. Governments and EU institutions are also encouraging public-private collaborations to accelerate R&D and scale new technology.

On December 2023, Merck, a leading science and technology company, has launched AIDDISON drug discovery software, the first software-as-a-service platform that bridges the gap between virtual molecule design and real-world manufacturability by integrating the Synthia retrosynthesis software application programming interface (API). It uses generative AI, machine learning, and computer-aided drug design to accelerate medication development.

Competition Analysis:

The in silico drug discovery market is characterized by a fragmented structure, with several players competing across various segments and regions. list of major players included in the in silico drug discovery market report are:

• Dassault System
• Evotec A.G.
• Acellera Ltd
• Charles River Laboratories International, Inc.
• Certara USA, Inc.
• Openeye (Cadence Molecular Sciences)
• Icagen, Inc
• Chemical Computing Group ULC
• Schrödinger, Inc.
• Genscript Biotech Corporation
• Albany Molecular Research Inc.
• Novo Informatics Pvt. Ltd
• Profacgen
• Selvita
• Sygnature Discovery

Strategic Developments in In Silico Drug Discovery Market:

• In May 2025, Molecular Forecaster Inc. and Oxeltis S.A. have established a strategic agreement that will combine their expertise to provide seamless integration of in silico design and high-quality chemical synthesis. MFI and Oxeltis will collaborate to assist enterprises prioritize candidates, minimize design cycles, and increase productivity by combining MFI’s predictive modeling and tailored, collaborative CADD solutions with Oxeltis’ wet lab-based medicinal chemistry design and synthesis services.
• In January 2025, BIMINI Biotech, an innovative Leiden-based drug research business developing novel therapies for hematological cancers, has successfully closed a EUR 3 million seed funding round. Cutting-edge computer-aided drug design and the research expertise of Expert Systems, an advanced accelerator platform with a comprehensive, hybrid AI-based system covering the entire preclinical drug discovery and early development stages will aid BIMINI’s activities.
• In November 2024, NVIDIA announced that worldwide pharmaceutical and techbio industry leaders, academic pioneers, and AI researchers will use the open-source NVIDIA BioNeMo Framework to improve drug discovery and molecule design. Researchers demand specialized biomolecular models and databases that allow them to collect large-scale insights to build treatments faster. The open-source BioNeMo Framework provides a set of accelerated computing tools for exponentially scaling AI models for biomolecular research, ushering in a new era of supercomputing in biopharma.

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2022 to 2023, with 2024 serving as the base year for market size calculations. The forecast period extends from 2025 to 2032.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights Of The In Silico Drug Discovery Market Report:

The In Silico Drug Discovery market report offers a detailed analysis of market size, including historical revenue (in USD Million) data for 2022-2023 and revenue forecasts for 2025-2032 across the following segments:

• Type Outlook (Revenue, USD Million; 2022-2032)
  • Software
    • Molecular Modeling & Simulation Software
    • Docking Software
    • Virtual Screening Tools
    • Bioinformatics Platforms
    • Others
  • Services
    • Target Identification & Validation Services
    • Lead Identification & Optimization Services
    • ADMET Prediction Services
    • Others
• Workflow Outlook (Revenue, USD Million; 2022-2032)
  • Target Identification & Validation
    • Genome & Protein Analysis
    • Structure-Based Target Prediction
    • Pathway & Network Analysis
  • Hit Identification
    • Ligand-Based Virtual Screening
    • Structure-Based Virtual Screening
  • Lead Optimization
  • Preclinical & Clinical Trial Simulation
• Technology Outlook (Revenue, USD Million; 2022-2032)
  • De novo drug design
  • Flexible ligand and flexible receptor docking
  • Molecular dynamics simulations
  • Scaffold hopping
  • Molecular docking
  • Others
• Type of Molecule Outlook (Revenue, USD Million; 2022-2032)
  • Antibodies
    • Monoclonal Antibodies
    • Antibody Fragments
    • Bispecific Antibodies
    • Polyclonal Antibodies
  • Proteins
    • Enzyme Inhibitors
    • Protein-Protein Interaction Modulators
  • Peptides
    • Therapeutic Peptides
    • Peptide-Drug Conjugates
  • Nucleic acids
    • Antisense Oligonucleotides
    • Small Interfering RNAs (siRNAs)
    • CRISPR-Cas gene editing tools
• Therapeutic Area Outlook (Revenue, USD Million; 2022-2032)
  • Oncology
  • Neurology
  • Infectious Diseases
  • Cardiovascular Disorders
  • Metabolic Disorders
  • Immunology & Inflammatory Diseases
  • Rare & Orphan Diseases
• End-Use Outlook (Revenue, USD Million; 2022-2032)
  • Pharmaceutical and Biopharmaceutical Companies
  • Contract Research Organizations
  • Academic and Research Institutes
• Regional Outlook (Revenue, USD Million; 2022-2032)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about the In Silico Drug Discovery market report